Company Jaguar Health, Inc.

JAGX

US47010C8626

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 10/07/2026 am IST			5-day change	1st Jan Change
2.370 ^USD	-1.66%		-15.66%	-92.73%

25/06	Jaguar Health, Inc., Napo Pharmaceuticals, Inc., And Woodward Specialty LLC Amend Manufacturing And Supply Agreement	CI
24/06	Jaguar Health Initiates Strategic-Alternatives Review Ahead of Crofelemer NDA Filing for Rare Intestinal Failure Program	CI

Business description: Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Number of employees: 47

Sales by Activity: Jaguar Health, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Human Health	42.73L	1.17Cr	95.88L	1.14Cr	1.12Cr
Animal Health	62T	2L	2L	3L	4L

See all business segments

Geographical breakdown of sales: Jaguar Health, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: Jaguar Health, Inc.

Manager	Title	Age	Since
Lisa Conte CEO	Chief Executive Officer	67	06/06/2013
Carol Lizak DFI	Director of Finance/CFO	62	13/08/2019
Jonathan Wolin CMP	Compliance Officer	64	01/11/2018
Pravin Ramsewak Chaturvedi CTO	Chief Tech/Sci/R&D Officer	63	01/03/2022
Ismaila Sougoufara AUD	Comptroller/Controller/Auditor	-	01/01/2020

See JAGUAR HEALTH, INC. governance

Composition of the Board of Directors: Jaguar Health, Inc.

Director	Title	Age	Since
Lisa Conte BRD	Director/Board Member	67	06/06/2013
James Bochnowski CHM	Chairman	82	01/06/2014
John Micek BRD	Director/Board Member	73	01/04/2016
Jonathan Siegel BRD	Director/Board Member	52	29/03/2018
Anula Kusum Jayasuriya BRD	Director/Board Member	69	01/07/2022

Composition of the Board of Directors

Shareholders: Jaguar Health, Inc.

Name	Stocks	%	Valuation
Streeterville Capital LLC 6.395 %	38,571	6.395 %	136 927 $
Joshua Mailman 2.782 %	16,780	2.782 %	59 569 $
Iliad Management Ltd. 2.084 %	12,571	2.084 %	44 627 $
UBS Group AG (13f Subfiler) 0.5233 %	3,156	0.5233 %	11 204 $
Geode Capital Management LLC 0.5216 %	3,146	0.5216 %	11 168 $

List of JAGUAR HEALTH, INC. shareholders

Company details: Jaguar Health, Inc.

Jaguar Health, Inc.

200 Pine Street

94104, San Francisco

http://www.jaguar.health

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JAGUAR HEALTH, INC.	-1.66%	-15.66%	-97.43%	-99.99%	14.29L
ELI LILLY AND COMPANY	+0.09%	+0.25%	+54.65%	+169.19%	1,08500Cr
JOHNSON & JOHNSON	-1.63%	-1.50%	+65.79%	+62.70%	62TCr
ABBVIE INC.	-1.12%	-4.27%	+31.10%	+84.44%	44TCr
ROCHE HOLDING AG	+0.88%	-0.68%	+28.63%	+27.54%	33TCr
ASTRAZENECA PLC	-1.64%	-8.90%	+23.94%	+29.37%	28TCr
NOVARTIS AG	+0.41%	-2.35%	+25.91%	+45.63%	28TCr
NOVO NORDISK A/S	+0.36%	-1.71%	-29.47%	-39.48%	22TCr
AMGEN INC.	-1.19%	-2.81%	+22.63%	+66.30%	20TCr
GILEAD SCIENCES, INC.	-0.72%	+2.72%	+19.07%	+81.19%	17TCr
Average	-0.35%	-3.24%	+14.48%	+42.69%	36.22TCr
Weighted average by Cap.	+0.12%	-1.06%	+38.31%	+85.09%